Relay Therapeutics(US:RLAY)2025-11-06 21:12Financial Performance - As of September 30, 2025, Relay Therapeutics reported cash, cash equivalents, and investments totaling $596.4 million, down from $781.3 million as of December 31, 2024[7]. - Research and development expenses for Q3 2025 were $68.3 million, a decrease of $8.4 million compared to $76.6 million in Q3 2024, primarily due to strategic streamlining[8]. - General and administrative expenses decreased to $12.1 million in Q3 2025 from $19.8 million in Q3 2024, reflecting a reduction in stock compensation and employee costs[9]. - The net loss for Q3 2025 was $74.1 million, or $0.43 per share, compared to a net loss of $88.1 million, or $0.63 per share, in Q3 2024[9]. - Total revenue for the nine months ended September 30, 2025, was $8.4 million, down from $10.0 million for the same period in 2024[16]. - Relay Therapeutics' total assets as of September 30, 2025, were $670.0 million, down from $871.3 million as of December 31, 2024[18]. Future Outlook - The company expects its current cash resources to be sufficient to fund operating expenses and capital expenditures into 2029[7]. Clinical Development - Relay Therapeutics is advancing its RLY-2608 clinical trials in PI3Kα-mutated breast cancer and vascular malformations[1]. - The ongoing Phase 3 ReDiscover-2 trial of RLY-2608 in advanced breast cancer continues to progress[11]. Corporate Governance - The company appointed Lonnel Coats and Habib Dable to its Board of Directors, bringing extensive commercialization expertise[3].